The influence of adequate debridement and placental-derived allografts on diabetic foot ulcers

Authors

William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCS, CWSP¹ ² ³ ⁴ ⁵ ⁶ ⁷*
Shawn M. Cazzell, DPM⁸
Brandon Hubbs, MS, MA¹
Julie L. De Jong, MS¹
R. Allyn Forsyth, PhD¹ ⁹
Alexander M. Reyzelman, DPM, FACFAS¹⁰ ¹¹

Corresponding Author: tarpon@xmission.com

Affiliations

¹ MIMEDX Group, Inc., GA, US.
² College of Podiatric Medicine, Western University of Health Sciences, US.
³ Duke University School of Medicine, Department of Anesthesiology, NC, US.
⁴ American Professional Wound Care Association, LA, US.
⁵ Association for the Advancement of Wound Care, PA, US.
⁶ Western Peaks Specialty Hospital, UT, US.
⁷ Encompass Health & Rehabilitation Hospital of Utah, US.
⁸ Limb Preservation Platform Inc., Fresno, CA, US.
⁹ Department of Biology, San Diego State University, San Diego, CA, US.
¹⁰ Department of Medicine, California School of Podiatric Medicine at Samuel Merritt University, CA, US.
¹¹ Co-Director, UCSF Center for Limb Preservation and Diabetic Foot Center for Clinical Research, San Francisco, CA, US.

Previous
Previous

Treatment patterns and outcomes of Medicare enrollees who developed venous leg ulcers

Next
Next

Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment